



Dkt. 57906-B/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William C. Olson, et al.
Serial No.: 09/594,983 Group Art Unit: 1648
Filed : June 15, 2001 Examiner: Shanon A. Foley
For : SYNERGISTIC INHIBITION OF HIV-1 FUSION AND
ATTACHMENT, COMPOSITIONS AND ANTIBODIES THERETO

1185 Avenue of the Americas
New York, New York 10036
September 13, 2002

Assistant Commissioner for Patents
U.S. Patent and Trademark Office, P.O. Box 2327
Arlington, VA 22202

RECEIVED

SEP 20 2002

Attn: Box Sequence

TECH CENTER 1600/2900

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted in connection with the above-identified application, has the same information as the pages attached hereto as **Exhibit B**, and entitled "Sequence Listing."

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Mark A. Farley

Mark A. Farley
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



57906-B.ST25

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

SEQUENCE LISTING

70610
<110> OLSON, WILLIAM C.
MADDON, PAUL J.

<120> SYNERGISTIC INHIBITION OF OF HIV-1 FUSION AND ATTACHMENT, C
OMPOSITIONS
AND ANTIBODIES THERETO

<130> 57906-B

<140> PCT/99US/30345

<141> 2000-06-15

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 31

<212> PRT

<213> HUMAN

Q1
<400> 1

Met Asp Tyr Gln Val Ser Ser Pro Ile Tyr Asp Ile Asn Tyr Tyr Thr
1 5 10 15

Ser Glu Pro Cys Gln Lys Ile Asn Lys Gln Ile Ala Ala Ala Arg
20 25 30

<210> 2

<211> 15

<212> PRT

<213> HUMAN

<400> 2

His Tyr Ala Ala Ala Gln Trp Asp Phe Gly Asn Thr Met Cys Gln
1 5 10 15

<210> 3
<211> 27
<212> PRT
<213> HUMAN

<400> 3

Arg Ser Gln Lys Glu Gly Leu His Tyr Thr Cys Ser Ser His Phe Pro
1 5 10 15

Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln
20 25

P1
<210> 4
<211> 17
<212> PRT
<213> HUMAN

<400> 4

Gln Glu Phe Phe Gly Leu Asn Asn Cys Ser Ser Ser Asn Arg Leu Asp
1 5 10 15

Gln
